One of the themes we have been watching out for at ASCO this year is new targets and novel combination strategies.

In each of the daily highlights we have selected five examples which jump out – for various reasons.

The early phase 1/2 trials obviously won’t be practice changing in the way a major global pivotal trial will be, yet they often offer useful clues for some of the new direections coming through company pipelines.

Today’s selection are a mix of early and late stage trials to ponder…

To learn more from our latest oncology review and get a heads up on key cancer research insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by